Connect with us

Government

Is The American Pendulum Swinging Back To Reason? Maybe, But It Will Be A Long Fight

Is The American Pendulum Swinging Back To Reason? Maybe, But It Will Be A Long Fight

Authored by Brandon Smith via Alt-Market.us,

It should…

Published

on

Is The American Pendulum Swinging Back To Reason? Maybe, But It Will Be A Long Fight

Authored by Brandon Smith via Alt-Market.us,

It should be considered an embarrassment for the states and districts involved, but the 2022 midterm elections are still being counted as I write this. In some cases, ballot drop boxes, mail-in ballots and “malfunctioning” voting machines have created a suspicious fog of uncertainty, and the uncertainty always seems to work in the favor of the political left.

Needless to say, some kind of change needs to happen – The majority of Americans are aware that ongoing trends of national deconstruction cannot be allowed to continue. Even the people that refrain from voting are watching the elections, just to see if the momentum of the country has shifted even a little. And, many people who tend to refrain are on the independent/libertarian side of things.

Times change and circumstances evolve, even if some people are too bitter or jaded to see it. The old guard Neocons trained in the Chicago school by Leo Strauss along with the acolytes of Irving Kristol are losing favor among conservative voters and many are dying out. The era of Bush family politics is going extinct; they were never conservative anyway.

What is left behind is a kind of philosophical stew – A mixture of libertarians, independents, Republicans and patriots that don’t necessarily affiliate with every aspect of the GOP but they will vote for a candidate with a strong stance against the woke propaganda and globalism of the political left. That’s what they are looking for.

For example, Ron DeSantis and his epic win in Florida shows us that the GOP is now being forced to address real conservative issues and concerns, whether they like it or not. Because if they want to win big like DeSantis they will have to start promoting the same policies and arguments as DeSantis. Republican candidates that don’t will not succeed, at least nowhere near the same level.

Many people assume that Trump was the impetus for this new wave of conservatives which has abandoned the Neocon coup. But in reality, the wave started at least a decade ago and we are only now beginning to see the results. Trump rode the wave, he didn’t create it.

Despite the claims of the mainstream media, there was indeed a red wave this year, but at the state level and in terms more subtle.

I consider keeping my own state red a matter of urgency. Montana conservatives recently witnessed what happens when we get lazy about voting leftists out of power. Our governor at the beginning of the covid event was Steve Bullock, a Democrat posing as a “middle of the road” pro-gun, pro-freedom guy. But when the federal government’s calls for mandates hit, Bullock followed right along with all other blue state politicians in trying to enforce unconstitutional restrictions and was incredibly malicious towards groups questioning such policies.

In 2020, we booted him out of office and most Democrats along with him. We learned our lesson – Keep the state red because in the event of crisis these people will exploit the situation to steal power and assert dominance.

I’ve had a lot of folks tell me over the years that voting is irrelevant and that conservative leaders at the state and county level would fold and submit to the whims of the feds when the time came for our liberties to be stripped away. These people were wrong.

The time did come; the pandemic was the perfect opportunity for establishment authoritarians to take all that was left of our freedoms forever. They certainly tried with all the tools available to them, including the controlled corporate media, big tech social media platforms, federal bureaucracy, etc. We passed within a short breath of full-spectrum tyranny.

The covid cult failed and they failed because red states across the country refused to comply, from the voters to the politicians. Conservative state leaders did not “fold” as many predicted, which means there is a chance to fight back on a level beyond defending our front porches with guns in hand.

At the very least, the actions of red states have bought us more time, and that is a precious commodity in an era of quickly escalating crisis. The situation is not quite as dire as I believed many years ago, and not as definitive as many liberty activists believe now. The end is not nigh. Our efforts are having an effect.

Am I putting blind faith in the elections? No. But there is valuable information to be derived from the elections and some of it tells a story of a country battling back from the brink of progressive insanity. Here are just a few factors to consider after the midterms:

Conservatives Were Out In Force

While the media constantly mentions a higher turnout for young voters this season, the real news is that conservatives had at least 3.5 million more voters overall than Democrats. Since the leftists are so fond of majority rule, it is interesting to point out the separation in active voters.

It is also odd that Democrats continue to declare “victory” in 2022 given they lost control of the House of Representatives. How can they declare a win when they came out the other side of the election with less than they had before?

Florida Sweep

Ron DeSantis crushed leftists in Florida based on a very vocal anti-woke, anti-establishment platform. He proved that this is what Americans want. Not middle of the road, not riding the fence or trying to be diplomatic, but remaining steadfast and uncompromising in the face of irrational zealotry and underhanded agendas.

Some people in the liberty movement have their complaints about DeSantis, but what I’m looking at is results and he has done more to stop the woke agenda in his state than any other state in the country. He also stood firm against covid authoritarianism. Results are what matter most.

The “Blue Invasion” Threat Was A Lie

All the wailing and screaming I heard over the past two years about leftists relocating into red states during covid and changing the demographics was complete nonsense. I’ve been saying since the pandemic began – Leftists don’t move away from their hive and they aren’t taking over red states, at least not in the past few years. The latest midterms prove that the fear of “blue invasion” was pure paranoia. If anything, in Montana we saw far more conservatives escaping blue states to live somewhere they felt was safe.

After this election I don’t want to hear another half-baked theory about the Dems turning Texas or Florida or other strong red states to the dark side.

The Abortion “Blue Wave” Never Happened

Remember after the Supreme Court decision overturning Roe v. Wade the number of media outlets proclaiming that conservatives would be destroyed during the elections? Apparently, average Americans are not as concerned with the “right” to kill babies as they had assumed. States that have moved to ban abortion are not facing a blue wave and these laws will most likely remain in place.

This fact upends a long running narrative in the mainstream than any attempt to stop abortion is doomed to failure and that any political candidate that supports banning abortion would be soundly defeated. The narrative was merely a scare tactic to create a false consensus.

Ballot Harvesting And Mail-In Options Always Favor Democrats

One could debate the reasons why, but the Democrat tactic of relying on non-traditional voting methods always works in their favor. There is also the issue of potential voter fraud when it comes to mail-in ballots and ballot harvesting, as we are currently seeing investigated by the Attorney General of Arizona. The only way to be sure that such sabotage does not occur is to do what Florida did and require most voters to appear at polls in person.

In battleground states where this is not an option, it would seem that conservatives are going to have to learn the ballot harvesting game that Democrats play and use the tactic against them.

Americans Place The Economy Above All Other Concerns

Regardless of how the elections pan out, public polling before the midterms consistently revealed that the majority of Americans are worried about inflation and economic decline above all else, and the social issues that leftists typically run on are at the bottom of the list.

This means that the longer the economic crisis goes on the more Dems in power will be questioned about their solutions. It is perhaps ironic that leftists are so keen to hold onto government control when they are only going to continue to take the bulk of the blame for the continuing economic fallout.

They have no plan, and they don’t intend to do anything about it except spend more money they don’t have, which is what caused the crisis in the first place. At least conservative candidates are acknowledging the threat; leftists still refuse to admit the threat exists.

I believe the economic danger will continue to grow, and there is little that can be done about it with Democrats still clinging to the Senate and with Biden in the White House. Which means the work will fall to individual states to protect themselves from the shock. I suspect that in the end red states will survive while blue states implode.

Is our cultural pendulum swinging back to reason? Yes, I see signs of it everywhere, but the fight ahead is going to be long and arduous. It’s not just the globalists that we have to contend with, it’s the woke activists and useful idiots within our population that need to be diminished. It took decades for us to get to the terrible spot we are in as a society and it will most likely take decades to get us out of it. That said, there is hope. Over time this fight can be won and there a many millions of us at the ready.

*  *  *

If you would like to support the work that Alt-Market does while also receiving content on advanced tactics for defeating the globalist agenda, subscribe to our exclusive newsletter The Wild Bunch Dispatch.  Learn more about it HERE.

Tyler Durden Mon, 11/21/2022 - 16:20

Read More

Continue Reading

Government

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…

Published

on

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

Trending